Invesco BulletShares 2029 Corporate Bond ETF (NASDAQ: BSCT)

에 대한 최신 뉴스 Invesco BulletShares 2029 Corporate Bond ETF (NASDAQ:BSCT)

The Fund generally will invest at least 80 percent of its total assets in securities that comprise the Underlying Index. Strictly in accordance with its guidelines and mandated procedures, Invesco Indexing LLC (the Index Provider) compiles and maintains the Underlying Index. The Underlying Index seeks to measure the performance of a portfolio of U.S. dollar-denominated investment grade corporate bonds with maturities or, in some cases, effective maturities in the year 2029 (collectively, 2029 Bonds). Certain bonds in which the Fund may invest may contain embedded issuer call options. An embedded issuer call option means that the bonds issuer has the right to redeem a bond prior to its designated maturity date. 

Invesco BulletShares 2029 Corporate Bond ETF

In the last three months, 5 analysts have published ratings on Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $250.4, a high estimate of $275.00, and a low estimate of $227.00. Experiencing a 4.57% decline, the current average is now lower than the previous average price target of $262.40. 
<img src="https://www.benzinga.com/files/images/story/2024/1734375625_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Teleflex's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$227.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$245.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$255.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$275.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Teleflex. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teleflex compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Teleflex's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Teleflex's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TFX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teleflex analyst ratings.</a>
<h2>Unveiling the Story Behind Teleflex</h2>
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
<h3>Teleflex: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Teleflex displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 2.41%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teleflex's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 14.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Teleflex's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.46%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Teleflex's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.49%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Teleflex's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.42.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Where Teleflex Stands With Analysts

Nutanix's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NYSE">NTNX</a>) short percent of float has risen 43.04% since its last report. The company recently reported that it has 7.56 million shares sold short, which is 3.29% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.57 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Nutanix Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734375621_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Nutanix has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Nutanix's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Nutanix's peer group average for short interest as a percentage of float is 2.81%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

NTNX

Peering Into Nutanix's Recent Short Interest

Analysts' ratings for CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $40.86, a high estimate of $46.00, and a low estimate of $35.00. This upward trend is apparent, with the current average reflecting a 22.96% increase from the previous average price target of $33.23.
<img src="https://www.benzinga.com/files/images/story/2024/1734375616_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of CarGurus among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$46.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$46.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Naved Khan</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$38.50</td>
<td>$26.50</td>
</tr>
<tr>
<td>Jed Kelly</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Marvin Fong</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>John Colantuoni</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CarGurus. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CarGurus compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for CarGurus's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CarGurus's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CARG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CarGurus analyst ratings.</a>
<h2>Unveiling the Story Behind CarGurus</h2>
CarGurus Inc is a company that acts as an online automotive marketplace connecting buyers and sellers of new and used cars. The company provides three types of marketplace Listing products, Restricted Listings, and Enhanced or Featured Listing through which it offers real-time and historical data analyzing the connections and pricing analysis. The listing platforms offer auto manufacturers and others to buy advertising on the company's site and target consumers based on the make, model, and zip code of the cars. The company operates through two segments namely U.S. Marketplace and Digital Wholesale. It generates majority of revenue from the U.S. Marketplace.
<h3>Unraveling the Financial Story of CarGurus</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: CarGurus's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 5.44%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.73%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): CarGurus's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.81% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): CarGurus's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.94% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: CarGurus's debt-to-equity ratio stands notably higher than the industry average, reaching 0.39. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CARG

Assessing CarGurus: Insights From 11 Financial Analysts

Legend Biotech's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NYSE">LEGN</a>) short percent of float has risen 3.93% since its last report. The company recently reported that it has 23.81 million shares sold short, which is 24.57% of all regular shares that are available for trading. Based on its trading volume, it would take traders 15.43 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Legend Biotech Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734375616_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Legend Biotech has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Legend Biotech's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Legend Biotech's peer group average for short interest as a percentage of float is 10.92%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

LEGN

(LEGN) - Analyzing Legend Biotech's Short Interest

Despite <a href="https://www.benzinga.com/real-estate/24/12/42462666/plan-and-budget-for-the-mid-6-range-what-homebuyers-can-expect-in-2025-according-to-realtor-com#:~:text=Home%20prices%20are%20expected%20to,following%202024's%20projected%204%25%20increase.">high mortgage rates squeezing the national housing market</a>, several Sun Belt cities are set for explosive sales growth in 2025, with Colorado Springs leading an anticipated surge of up to 27% in transaction volume.
The military-heavy Colorado City tops Realtor.com's annual housing forecast, followed by Miami and Virginia Beach, where existing home sales are projected to jump 24% and 23.4%, respectively. These increases dwarf the modest 1.5% growth expected nationwide.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-y2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl-y2"> you can become an investor for $0.80 per share today.</a></li>
</ul>
&#8220;Although affordability is still stretched for many households in these markets, as is the case just about everywhere, aspiring homeowners are able to create opportunities and access homeownership as a result of government-backed loan programs that enable lower down payments,&#8221; Danielle Hale, Realtor.com's chief economist, said in the report.
The forecast heavily favors the South and West, with Texas placing multiple cities in the top rankings. El Paso and McAllen, offering median list prices under $290,000, are projected to increase sales by 19%. According to the report, the Texas markets benefit from military presence, international connections and remote work flexibility.
See Also: During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes-y2"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a>
Local dynamics drive growth in Miami, where sales are expected to surge 24% despite a median list price of $525,000. &#8220;The real estate market buzzes with activity as both locals and international buyers flock to seize the opportunity to invest in this sunny paradise,&#8221; Miami real estate agent Branden Rivero said.
Virginia's strong showing includes Virginia Beach and Richmond in the top five, with projected increases of 23.4% and 21.6%. The coastal region's military concentration – the largest outside the Pentagon – bolsters the market through VA loan accessibility.
Trending: <a href="https://www.benzinga.com/go/arrived-private-credit-yf">Arrived Home's Private Credit Fund&#8217;s has historically paid an annualized dividend yield of 8.1%&#x2A;</a>, which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum.<a href="https://www.benzinga.com/go/arrived-private-credit-yf">&nbsp;</a>
Washington D.C., expecting 17% sales growth, offers an urban alternative to pricier metros. "DC is drawing people in that don't quite want the busyness of New York City but still favor good restaurants, lots of things to do and a top-rated mass transit system," says Cedric Stewart, a Keller Williams real estate expert.
Common threads among the growth markets include recent sales momentum, <a href="https://www.benzinga.com/real-estate/24/12/42312110/more-inventory-should-shake-loose-in-2025-says-zillow-chief-economist">substantial inventory often driven by new construction</a> and demographics skewing younger. Many feature high rates of outright homeownership without mortgage debt, helping buffer against interest rate pressures.
Charlotte is an example of the broad appeal driving the projections. &#8220;The Charlotte market is one of the fastest-growing real estate markets in the country, with over 100 people moving to Charlotte a day,&#8221; Kate Terrigno of Corcoran HM Properties was quoted in the report.
Read Next:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes-y2">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
</ul>

Markets

2025's Top Housing Markets: Where Home Sales Will Jump By Up To 27%, According To Report

Western Midstream's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WES#NYSE">WES</a>) short percent of float has fallen 3.26% since its last report. The company recently reported that it has 6.18 million shares sold short, which is 3.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Western Midstream Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734375610_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Western Midstream has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Western Midstream's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Western Midstream's peer group average for short interest as a percentage of float is 4.23%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(WES) - Analyzing Western Midstream's Short Interest

Throughout the last three months, 17 analysts have evaluated C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">11</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for C.H. Robinson Worldwide, presenting an average target of $114.82, a high estimate of $140.00, and a low estimate of $85.00. Surpassing the previous average price target of $103.38, the current average has increased by 11.07%.
<img src="https://www.benzinga.com/files/images/story/2024/1734375608_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of C.H. Robinson Worldwide's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>J. Bruce Chan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$112.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Jason Seidl</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$119.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Fadi Chamoun</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$118.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Garrett Holland</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$124.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Christian Wetherbee</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Ariel Rosa</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Jordan Alliger</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$107.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Bascome Majors</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Jason Seidl</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$113.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Fadi Chamoun</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$115.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Jordan Alliger</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$97.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ariel Rosa</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$115.00</td>
<td>-</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jonathan Chappell</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$122.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Bascome Majors</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to C.H. Robinson Worldwide. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of C.H. Robinson Worldwide compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for C.H. Robinson Worldwide's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into C.H. Robinson Worldwide's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CHRW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on C.H. Robinson Worldwide analyst ratings.</a>
<h2>Discovering C.H. Robinson Worldwide: A Closer Look</h2>
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 61% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (27%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
<h3>C.H. Robinson Worldwide: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: C.H. Robinson Worldwide's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 6.99%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: C.H. Robinson Worldwide's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.09% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): C.H. Robinson Worldwide's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.17% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): C.H. Robinson Worldwide's ROA excels beyond industry benchmarks, reaching 1.75%. This signifies efficient management of assets and strong financial health.
Debt Management: C.H. Robinson Worldwide's debt-to-equity ratio is below the industry average. With a ratio of 1.17, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHRW

What Analysts Are Saying About C.H. Robinson Worldwide Stock

WIIM

ADUS

Addus HomeCare shares are trading higher. JMP Securities initiated coverage on the stock with a Market Outperform rating and announced a price target of $150.

Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) may have bright days thanks to theme parks and streaming, according to Rosenblatt&#8217;s Barton Crockett.
The Disney Analyst: Crockett maintains a Buy rating on Disney and raised the price target from $122 to $135.
The Analyst Takeaways: Disney's growth looks "do-able" and the stock is "buyable," Crockett writes in a new investor note.
Read Also: <a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance">Disney Q4 Earnings: Revenue And Profit Beat, Best Film Studio Performance, 3-Year Outlook And More</a>
The new $135 price target assumes Disney shares can trade closer to a forward price-to-earnings ratio of 22x, instead of the near 10% discount to the market average Disney stock has traded at in recent history.
"A northward re-rating for Disney can be supported by rising confidence in portfolio durability and growth trajectory, and less concern about exposure to secular pressures on linear TV and competition in streaming," Crockett said.
Disney's confidence in high single-digit earnings per share growth in 2025, and double-digit growth in 2026 and 2027 appears aggressive, Crockett says. But it could become a reality, he adds, after hearing more details from new CFO Hugh Johnson last week.
Disney remains focused on its theme park segment<a href="https://www.benzinga.com/markets/equities/24/12/42382381/disney-doubles-down-on-cruises-with-seven-new-ships-by-2031-targets-asian-market-expansion-best-time-to-invest-in-this-business"> and cruise lines</a>, which will continue to attract guests in future.
Disney's DTC segment, which includes Hulu, Disney+ and ESPN streaming platforms, could also be a key growth element, Crockett said.
The analyst said cross-promotion reduced churn and Disney+ is enjoying a lift in subscribers thanks to several hit films. <a href="https://www.benzinga.com/general/entertainment/24/11/42123085/wicked-gladiator-ii-moana-2-could-break-thanksgiving-weekend-box-office-stocks-to-watch">The release of movies</a> like "Deadpool &amp; Wolverine," "Inside Out 2" and "Moana 2" on Disney+ could help boost subscriber growth ahead.
Crockett says DTC streaming is &#8220;the leading driver of segment profit growth in F2026.&#8221;
Price Action: Disney stock is down 0.58% to $112.41 on Monday versus a 52-week trading range of $83.91 to $123.74. Disney stock is up 24% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42422496/inside-out-2-deadpool-wolverine-baby-reindeer-dominate-entertainment-searches-on-google-in-2024-top-10-movies-tv-shows-and-more">&#8216;Inside Out 2,&#8217; &#8216;Deadpool &amp; Wolverine,&#8217; &#8216;Baby Reindeer&#8217; Google&#8217;s Top 2024 Entertainment Searches</a></li>
</ul>
Image: Shutterstock

Analyst Color

Entertainment

Price Target

Reiteration

Disney Analyst Highlights Streaming, Theme Parks And 'Portfolio Durability'

Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) will conduct an investor call on Tuesday to provide full-year 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42415564/pfizer-invites-public-to-view-and-listen-to-webcast-of-december-17-conference-call-with-analysts-t" rel="noreferrer noopener">financial guidance</a>.
Ahead of the call, Goldman Sachs has outlined its expectations for the guide and commentary on the upcoming year.
The analyst anticipates that Pfizer&#8217;s management will guide to EPS in the mid-to-high $2 range with core business growth offset by the $0.30 in favorable but non-recurring items during 2024.
Pfizer highlighted several factors affecting its 2024 EPS that won&#8217;t carry over to 2025.
The 2024 EPS includes one-time boosts: a $1.2 billion benefit <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41596761/pfizer-q3-earnings-revenue-and-profit-on-heightened-demand-for-paxlovid-expects-10-billion-in-202" rel="noreferrer noopener">from Paxlovid stockpiling</a> and a U.S. government true-up and equity income from its stake in Haleon Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>). However, Haleon income will not appear in 2025, as Pfizer&#8217;s ownership in Haleon is <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41112790/pfizer-divests-3-3b-stake-in-sensodyne-toothpaste-and-panadol-painkiller-maker-haleon" rel="noreferrer noopener">dropping below 20%</a>.
Goldman forecasts for 2025 revenues of $64.9 billion and EPS of $3.13, which compares to consensus estimates of $63.2 billion and $2.89, respectively.
Goldman Sachs notes that the impact of the IRA Part D redesign will likely be addressed in the company&#8217;s 2025 guidance. However, the analyst does not expect the details to be broken down by individual products but instead based on the overall commercial portfolio.
The analyst expects Paxlovid sales of $4.3 billion vs. consensus of $3.7 billion, though slightly more conservative on Vyndaqel sales of $5.9 billion vs. consensus of $6.2 billion.
Year-to-date, Eliquis has performed well, showing 12% growth thanks to market expansion and increased market share. This growth has been supported by Pfizer&#8217;s commercial team and boosted by Part D catastrophic coverage in 2024.
Looking ahead to 2025, Pfizer expects continued growth opportunities driven by market expansion and the potential for further share gains.
&#8220;We highlight dynamics across key topics and frame potential points of discussion with potential read-across beyond Pfizer specifically, noting that they are the only large cap pharma company in our coverage that we expect to opine on 2025 ahead of the new year,&#8221; Goldman analyst writes.
Price Action: PFE stock is down 0.39% at $25.48 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42507348/ozempic-maker-novo-nordisk-invests-over-1-billion-in-new-production-facility-in-denmark-comes-closer-to-add-three-more-from-catalent" target="_blank" rel="noreferrer noopener">Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent</a></li>
</ul>
Photo via Shutterstock.

Biotech

Earnings

Equities

Large Cap

News

Guidance

Health Care

General

What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?

JMP Securities initiated coverage on Addus HomeCare Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>), a provider of home-based personal care and clinical services.
JMP analysts see Addus HomeCare as having a uniquely strong and well-established presence in personal care services across multiple states, thanks to the company's scale and experienced management team.
The analyst writes that personal care is a cost-effective way to provide home-based services, especially as the U.S. faces a shortage of expensive skilled clinicians.
This approach also helps delay the need for more costly care options. With the highly fragmented personal care sector, Addus has opportunities to expand by adding complementary home health and hospice services to its existing markets.
The analysts expect this strategy to support sustained double-digit revenue growth for the company in the coming years.
In the third quarter, Addus HomeCare revenues were $289.8 million for the third quarter of 2024, a 7.0% increase compared with $270.7 million for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41727154/addus-homecare-announces-third-quarter-2024-financial-results" rel="noreferrer noopener">the third quarter of 2023</a>.
JMP has initiated with a price target of $150, with <a target="_blank" href="https://www.benzinga.com/quote/ADUS/analyst-ratings" rel="noreferrer noopener">a Market Perform rating</a>.
Addus HomeCare recently acquired Gentiva's PC operations. The deal, the largest acquisition in the company's history, is expected to allow Addus HomeCare to enter Texas with critical mass and add personal care services in six other states, three of which are <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42276478/addus-homecare-completes-acquisition-of-personal-care-operations-of-gentiva" rel="noreferrer noopener">new to the company</a>.
Gentiva's PC platform is expected to contribute annual revenue of $275 million-$280 million, prompting 29% year-over-year personal care growth for Addus HomeCare in 2025, above the segment's five-year CAGR (2019-2024E) of 8%.
JMP writes that in recent years, Addus HomeCare has expanded into value-based care (VBC) arrangements in select markets through its "Care Advantage" program.
The company is well-positioned to grow in this area thanks to its combination of clinical and non-clinical care resources, along with its large-scale operations and robust case management systems.
Price Action: ADUS stock is up 5.14% at $131.42 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/24/12/42505835/honeywell-advances-strategic-review-explores-aerospace-business-separation" target="_blank" rel="noreferrer noopener">Honeywell Advances Strategic Review, Explores Aerospace Business Separation</a></li>
</ul>
Photo via Shutterstock

Initiation

Movers

As US Faces Shortage Of Expensive Skilled Clinicians, Home-Based Health Service Provider Addus HomeCare Is Well-Positioned To Grow: Analyst

<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1200" height="711" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/16185231/image-7.png" alt="" class="wp-image-4139" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/16185231/image-7.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/16185231/image-7-300x178.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/16185231/image-7-1024x607.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/16185231/image-7-768x455.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Small Language Model</h4>
An enlarged chart of Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock.&nbsp; The chart of MSFT stock is being used to illustrate the point.</li>
<li>The chart shows MSFT stock has climbed in December so far.</li>
<li>The chart shows support and resistance zones for MSFT.</li>
<li>RSI on the chart shows MSFT stock is overbought.&nbsp; Overbought stocks are susceptible to a pullback.</li>
<li>The Arora Report previously shared with readers a major milestone in AI progress – human-like reasoning capabilities using chain link thinking in Model 4o from OpenAI.</li>
<li>ChatGPT-4o is a large language model.</li>
<li>In further AI progress, Microsoft has introduced Phi-4.&nbsp; Phi-4 is a small language model that outperforms GPT-4o in certain mathematical reasoning.&nbsp; Phi-4 is only a fraction of the size of GPT-4o.&nbsp; It appears that Phi-4 can do better in solving certain math problems compared to its teacher model GPT-4o.&nbsp; Also of note is that Microsoft trained Phi-4 mostly on synthetic data.</li>
<li>The foregoing is important for investors as investors need to get ahead of the curve.&nbsp; In The Arora Report analysis, Phi-4 challenges the present belief that bigger is better.</li>
<li>In The Arora Report analysis, small language models such as Phi-4 have a very bright future.&nbsp; There is a fortune to be made in AI between now and 2030.&nbsp; However, it will not be in a straight line.&nbsp; At times, it will be treacherous.</li>
<li>There is excitement in the stock market this morning as it was announced Friday after the close that AI software company Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) and big bitcoin holder MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) are being added to the Nasdaq 100.</li>
<li>The Arora Report has previously written that one of the things Trump can do to reduce inflation from his policies is to attract foreign investment to the U.S.&nbsp; In the first sign of success for Trump, Japan's SoftBank Group Corp &#8211; ADR (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) CEO Masayoshi Son will announce at Mar-a-Largo a $100B investment in the U.S. over the next four years.</li>
<li>There is also buying in the early trade as the market believes it is a certainty that the Fed will cut interest rates this week in spite of the data not supporting such a rate cut.</li>
<li>Markets in the U.S. are not being impacted by weakness in Europe and Asia as there was powerful pumping of stocks in the media over the weekend.&nbsp; Retail investors tend to be influenced by the weekend pump and buy on Monday morning.</li>
</ul>
<h4 class="wp-block-heading">France</h4>
Moody's has cut France's credit rating.&nbsp; French stocks and bonds are falling.
<h4 class="wp-block-heading">China</h4>
Markets all across the globe are being negatively impacted by weak retail sales data in China.
Retail sales in China came at 3.0% year-over-year vs 4.8% consensus.
Concern is building that the Chinese consumer is not spending in spite of stimulus measures by the government.
In The Arora Report analysis, investors should note the sharp contrast between U.S. consumers and Chinese consumers at this time.&nbsp; U.S. consumers are on a buying binge.&nbsp; Chinese consumers are holding back and are focused on savings.
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Amazon.com, Inc., Alphabet Inc Class C , Meta Platforms Inc , NVIDIA Corp , and Tesla Inc.
In the early trade, money flows are neutral in Apple Inc and Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>).
In the early trade, money flows are positive in SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.&nbsp; Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.&nbsp; The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).&nbsp; The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).&nbsp; The most popular ETF for oil is United States Oil ETF (ASCA:USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Over the weekend, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ran over $106,000 on a rumor that Trump will announce the bitcoin reserve on day 1.
<h4 class="wp-block-heading">Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider holding Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

$BTC

MSFT

MSTR

PLTR

SFTBY

AI Progress From Microsoft – Phi-4 Outperforms Human-like reasoner AI Model GPT-4o, Bitcoin Rumor

Tech stocks extended their rally to new heights on Monday, with the Nasdaq 100 index climbing over 1% to surpass 22,000 points, fueled by robust gains among key <a href="https://www.benzinga.com/tech">components in the index.</a>
Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) led the charge, soaring over 8% after receiving bullish price-target updates from analysts. The company's AI-driven growth potential gained further traction on Friday following its announcement of a collaboration with Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) to produce a cutting-edge AI chip.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) also rallied, jumping more than 5%, pushing its post-election gains to 85%, buoyed by positive analyst sentiment. Wedbush Securities described Tesla as a &#8220;game-changer&#8221; in AI and autonomous advancements under Trump's administration, adding to the bullish outlook.
Among other indices, the Russell 2000 rose 1%, while the S&amp;P 500 edged up 0.4%. The Dow Jones Industrial Average, however, dipped 0.2%, weighed down by losses in the energy and healthcare sectors.
On the economic front, private-sector surveys showed a stronger-than-expected rebound in December activity. The services sector Purchasing Managers&#8217; Index (PMI) surged to 58.5, the highest reading since October 2021. Meanwhile, the Composite PMI climbed to 56.6, its best level since April 2022, as robust growth in services offset continued weakness in manufacturing.
Crypto-related assets gained fresh bullish momentum, driven by speculation about the U.S. government creating a Bitcoin Strategic Reserve fund. Meanwhile, MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) will be added to the Nasdaq 100 Index on Dec. 23, further boosting sentiment.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) reached $107,000, marking a year-to-date gain of 153%. MicroStrategy shares rose 5.8%, while other crypto-linked stocks, such as MARA Digital Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>), Riot Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>), and Coinbase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), surged 11.1%, 9.2%, and 4.5%, respectively.
<h3 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1-day %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>22,043.82</td>
<td>1.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,369.39</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,076.94</td>
<td>0.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,750.42</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:15 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121624&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.5% to $607.34.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;eased 0.2% to $438.86.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 1.4% to $537.94.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1% to $235.13.</li>
<li>The&nbsp;Consumer Discretionary Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up by 1.2%; the&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1.8%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
<ul>
<li>Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) rose 7.1%, reflecting bullish investor sentiment ahead of its earnings report on Wednesday after the close.</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) rose by 4.7%, building up momentum after last week&#8217;s 8.7% surge following the announcement of the quantum computer launch. </li>
<li>Shares of of natural gas companies fell amid prospects for less colder weather in the upcoming weeks. New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) led industry declines, down 7%. </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42514008/fed-poised-to-cut-interest-rates-by-0-25-this-week-heres-why-your-focus-should-shift-to-other-signals">Fed Poised To Cut Interest Rates By 0.25% This Week: Here&#8217;s Why Your Focus Should Shift To Other Signals</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Mid Cap

Sector ETFs

Broad U.S. Equity ETFs

Small Cap

Econ #s

Economics

Tech

ETFs

AAPL

AVGO

COIN

SPDR Dow Jones Industrial Average ETF Trust

GOOGL

MARA

RIOT

TSLA

Select Sector SPDR-Consumer Discretionary

Broadcom, Tesla Propel Nasdaq 100 Gains, Bitcoin Hits $107,000, Fueling Crypto Stocks Rally: What's Driving Markets Monday?

CRWD

Crowdstrike shares are trading higher. JP Morgan maintained its Overweight rating on the stock and raised its price target from $372 to $418.

Investors with a lot of money to spend have taken a bearish stance on AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AVAV, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for AeroVironment.
This isn't normal.
The overall sentiment of these big-money traders is split between 21% bullish and 42%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $246,086, and 10 are calls, for a total amount of $620,396.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $105.0 and $185.0 for AeroVironment, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of AeroVironment stands at 97.25, with a total volume reaching 519.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in AeroVironment, situated within the strike price corridor from $105.0 to $185.0, throughout the last 30 days.
<h3>AeroVironment Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734374730_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVAV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$64.6</td>
<td>$60.9</td>
<td>$62.78</td>
<td>$105.00</td>
<td>$162.7K</td>
<td align="right">0</td>
<td align="right">26</td>
</tr>
<tr>
<td>AVAV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$62.4</td>
<td>$58.8</td>
<td>$60.59</td>
<td>$105.00</td>
<td>$157.0K</td>
<td align="right">50</td>
<td align="right">26</td>
</tr>
<tr>
<td>AVAV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.3</td>
<td>$8.2</td>
<td>$8.2</td>
<td>$165.00</td>
<td>$106.7K</td>
<td align="right">143</td>
<td align="right">130</td>
</tr>
<tr>
<td>AVAV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$26.7</td>
<td>$26.6</td>
<td>$26.6</td>
<td>$185.00</td>
<td>$79.8K</td>
<td align="right">139</td>
<td align="right">51</td>
</tr>
<tr>
<td>AVAV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$12.3</td>
<td>$12.0</td>
<td>$12.01</td>
<td>$160.00</td>
<td>$50.9K</td>
<td align="right">168</td>
<td align="right">84</td>
</tr>
</tbody>
</table>

<h3>About AeroVironment</h3>
AeroVironment Inc operates under a single business segment in which it supplies unmanned aircraft systems, tactical missile systems, high-altitude pseudo-satellites, and other related services to government agencies within the United States Department of Defense as well as the United States allied international governments. The systems can help with security, surveillance, or sensing, and provide eyes in the sky without needing an actual person, or driver in the sky.
<h3>Where Is AeroVironment Standing Right Now?</h3>
<ul>
<li>With a trading volume of 655,958, the price of AVAV is up by 1.92%, reaching $159.5.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 77 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for AeroVironment</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $230.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Jefferies has elevated its stance to Buy, setting a new price target at $230. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AeroVironment options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

AVAV

What the Options Market Tells Us About AeroVironment

Whales with a lot of money to spend have taken a noticeably bullish stance on Newmont.
Looking at options history for Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) we detected 20 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 40% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $437,295 and 14, calls, for a total amount of $1,356,261.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $55.0 for Newmont over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Newmont stands at 3573.42, with a total volume reaching 18,285.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Newmont, situated within the strike price corridor from $30.0 to $55.0, throughout the last 30 days.
<h3>Newmont 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734374725_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.42</td>
<td>$2.29</td>
<td>$2.39</td>
<td>$45.00</td>
<td>$358.5K</td>
<td>2.7K</td>
<td>1.5K</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$6.2</td>
<td>$6.1</td>
<td>$6.1</td>
<td>$35.00</td>
<td>$244.2K</td>
<td>631</td>
<td>400</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.25</td>
<td>$1.24</td>
<td>$1.25</td>
<td>$45.00</td>
<td>$237.0K</td>
<td>11.3K</td>
<td>2.2K</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$0.91</td>
<td>$0.9</td>
<td>$0.9</td>
<td>$35.00</td>
<td>$144.0K</td>
<td>6.7K</td>
<td>1.6K</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$3.85</td>
<td>$3.8</td>
<td>$3.85</td>
<td>$45.00</td>
<td>$115.1K</td>
<td>319</td>
<td>300</td>
</tr>
</tbody>
</table>

<h3>About Newmont</h3>
Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 5.5 million ounces of gold in 2024 from its core mines and 6.8 million in total. It is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2023.
Following our analysis of the options activities associated with Newmont, we pivot to a closer look at the company's own performance.
<h3>Current Position of Newmont</h3>
<ul>
<li>With a trading volume of 4,814,346, the price of NEM is down by -0.29%, reaching $40.1.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 66 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Newmont, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Market Whales and Their Recent Bets on NEM Options

Whales with a lot of money to spend have taken a noticeably bullish stance on Constellation Energy.
Looking at options history for Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 80% of the investors opened trades with bullish expectations and 10% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $475,500 and 4, calls, for a total amount of $284,500.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $250.0 for Constellation Energy, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Constellation Energy stands at 1269.86, with a total volume reaching 1,205.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Constellation Energy, situated within the strike price corridor from $200.0 to $250.0, throughout the last 30 days.
<h3>Constellation Energy Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734374720_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$16.7</td>
<td>$16.0</td>
<td>$16.75</td>
<td>$250.00</td>
<td>$190.8K</td>
<td align="right">816</td>
<td align="right">146</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$55.9</td>
<td>$54.6</td>
<td>$54.6</td>
<td>$200.00</td>
<td>$136.5K</td>
<td align="right">76</td>
<td align="right">25</td>
</tr>
<tr>
<td>CEG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.4</td>
<td>$28.8</td>
<td>$28.8</td>
<td>$220.00</td>
<td>$100.8K</td>
<td align="right">152</td>
<td align="right">35</td>
</tr>
<tr>
<td>CEG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$12.9</td>
<td>$12.3</td>
<td>$12.4</td>
<td>$220.00</td>
<td>$62.0K</td>
<td align="right">143</td>
<td align="right">50</td>
</tr>
<tr>
<td>CEG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$15.9</td>
<td>$15.1</td>
<td>$15.1</td>
<td>$210.00</td>
<td>$60.4K</td>
<td align="right">134</td>
<td align="right">40</td>
</tr>
</tbody>
</table>

<h3>About Constellation Energy</h3>
Constellation Energy Corp offers energy solutions. It provides clean energy and sustainable solutions to homes, businesses, the public sector, community aggregations, and a range of wholesale customers (such as municipalities, cooperatives, and other strategics). The company offers comprehensive energy solutions and a variety of pricing options for electric, natural gas, and renewable energy products for companies of any size.
<h3>Current Position of Constellation Energy</h3>
<ul>
<li>Trading volume stands at 963,178, with CEG's price up by 0.84%, positioned at $241.08.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 71 days.</li>
</ul>
<h3>What The Experts Say On Constellation Energy</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $295.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Constellation Energy, which currently sits at a price target of $322. 
&#x2A; In a positive move, an analyst from B of A Securities has upgraded their rating to Buy and adjusted the price target to $269. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Constellation Energy options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Check Out What Whales Are Doing With CEG

On Friday, Nasdaq Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) annual reconstitution of the Nasdaq-100 Index will become effective before the market <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42494812/annual-changes-to-the-nasdaq-100-index" rel="noreferrer noopener">opens on December 23</a>.
Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) was&nbsp;removed&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42495649/microstrategy-palantir-axon-added-to-nasdaq-100-super-micro-computer-moderna-illumina-exit-the-index" rel="noreferrer noopener">from the index</a>. Year to date, the stock has increased around 8%, underperforming iShares Core S&amp;P Mid-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IJH#NYSE">IJH</a>).
The provider of DNA sequencing and array-based technologies has been in the news due to its controversial multi-billion dollar deal to acquire cancer test maker Grail Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/m-a/24/09/40688420/european-court-rules-in-favor-of-illumina-in-fight-against-probe-into-grail-deal-asks-not-to-pay-478" rel="noreferrer noopener">European Court Rules In Favor Of Illumina In Fight Against Probe Into Grail Deal, Asks Not To Pay $478M Fine</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16125312/newplot-2-1.png" alt="" class="wp-image-694387" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16125312/newplot-2-1.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16125312/newplot-2-1-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Nearly four years after pitching for&nbsp;Grail,&nbsp;Illumina finally separated the&nbsp;<a target="_blank" href="https://www.benzinga.com/m-a/24/09/40688420/european-court-rules-in-favor-of-illumina-in-fight-against-probe-into-grail-deal-asks-not-to-pay-478" rel="noreferrer noopener">cancer blood test developer</a>.&nbsp;To expand its reach in single-cell analysis and&nbsp;multiomics research, Illumina <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39714633/illumina-buys-fluent-biosciences-to-gain-stronger-foothold-in-single-cell-analysis" rel="noreferrer noopener">acquired privately-held</a> Fluent BioSciences.
Also in March, activist investor&nbsp;Carl Icahn opted against pursuing a fresh challenge to Illumina&#8217;s board, which spares the U.S. gene sequencing company from facing its second proxy battle in consecutive years.&nbsp;
Previously, Icahn had expressed intentions to remove additional directors from Illumina&#8217;s board, attributing the company&#8217;s substantial market value decline and the ill-fated $7.1 billion Grail acquisition to mismanagement by the <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/03/37671511/gene-sequencing-firm-illumina-escapes-carl-icahns-second-proxy-battle-amid-grail-divestment-effort" rel="noreferrer noopener">existing board members</a>.&nbsp;
Most recently, Illumina reported third-quarter&nbsp;adjusted EPS of $1.14, beating the consensus of $0.88, with sales&nbsp;of $1.08 billion, almost in line with the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41727185/illumina-reports-financial-results-for-third-quarter-of-fiscal-year-2024" rel="noreferrer noopener">consensus of $1.08 billion</a>.
&#8220;During the third quarter, the Illumina team delivered strong operating results, and revenue met our expectations,&#8221; said&nbsp;Jacob Thaysen, Chief Executive Officer.
&#8220;The near-term macroeconomic environment remains constrained, and we are slightly lowering our 2024 revenue guidance,&#8221; Thaysen added.
Price Action: ILMN stock is down 0.12% at $143.70 at the last check on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42514376/whats-going-on-moderna-stock-on-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Moderna Stock On Monday?</a></li>
</ul>
Photo via Shutterstock

GRAL

ILMN

NDAQ

What's Going On With Illumina Stock On Monday?

On Friday, Nasdaq Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42494812/annual-changes-to-the-nasdaq-100-index" rel="noreferrer noopener">on December 23</a>.
As a result, Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) was&nbsp;removed&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42495649/microstrategy-palantir-axon-added-to-nasdaq-100-super-micro-computer-moderna-illumina-exit-the-index" rel="noreferrer noopener">from the index</a>. Year to date, Moderna stock has plunged over 60%, with a 52-week low-high of $35.8-$170.47, as per data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
Recently, Moderna and several other stocks witnessed a decline as Robert F. Kennedy Jr.'s, Donald Trump's nomination to lead the&nbsp;Department of&nbsp;Health and Human Services, is known to be against vaccines and has a track record of making false <a target="_blank" href="https://www.benzinga.com/24/11/42045488/moderna-remains-confident-despite-political-concerns-over-vaccine-safety-and-hhs-nomination" rel="noreferrer noopener">claims about vaccines</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42045488/moderna-remains-confident-despite-political-concerns-over-vaccine-safety-and-hhs-nomination" rel="noreferrer noopener">Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16123322/newplot-1-3.png" alt="" class="wp-image-694341" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16123322/newplot-1-3.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16123322/newplot-1-3-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
The company has witnessed a decline in its only approved product, Spikevax, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40104375/moderna-stock-sinks-on-lowered-2024-outlook-cites-low-european-sales-competitive-rsv-vaccine-mark" rel="noreferrer noopener">the COVID-19 vaccine</a>.
However, Moderna witnessed some relief on higher third-quarter sales attributed to higher sales in the U.S. market following the earlier launch of the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41854205/modernas-q3-earnings-beat-overshadowed-by-vaccine-demand-slowdown-and-market-share-concerns-analysts-warn" rel="noreferrer noopener">updated COVID-19 vaccine</a>.
Moderna&nbsp;unveiled key updates at its annual R&amp;D Day in September, spotlighting its mRNA-based pipeline and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40834547/moderna-outlines-post-covid-roadmap-cuts-research-budget-forecasts-2025-sales-below-expectations" rel="noreferrer noopener">revised financial plans</a>.
Faced with commercial challenges, Moderna is adopting a more selective approach to R&amp;D investments. The company anticipates maintaining substantial R&amp;D investment, especially in oncology and rare diseases, while pacing other expenditures.
Moderna is also facing several litigations, including the recently announced patent infringement lawsuit filed by Northwestern University. The lawsuit alleges that the pharmaceutical company used the university's lipid nanoparticle (LNP) technology without permission to develop&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41381861/moderna-hit-with-another-lawsuit-related-to-key-covid-19-vaccine-technology" rel="noreferrer noopener">its COVID-19 vaccines.</a>
GSK Plc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) also filed a lawsuit alleging that Moderna's mRNA vaccines infringe on&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41342286/gsk-sues-moderna-alleging-mrna-vaccine-patent-infringement" rel="noreferrer noopener">patents it developed</a>.
Price Action: MRNA stock is down 1.04% at $41.40 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42507816/taiwan-semiconductor-ceo-highlights-ai-powered-drones-next-gen-robots-as-growth-drivers" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor CEO Highlights AI-Powered Drones, Next-Gen Robots As Growth Drivers</a></li>
</ul>
Photo via <a href="https://commons.wikimedia.org/wiki/File:Moderna_COVID-19_vaccine_%282021%29_F.jpg">Wikimedia Commons</a>

Comments

Invesco BulletShares 2029 Corporate Bond ETF

뉴스

에 대한 최신 뉴스 Invesco BulletShares 2029 Corporate Bond ETF (NASDAQ:BSCT)

뉴스

파트너 / 기고자

벤징가 글로벌